PT-141 (Bremelanotide) Improves Sexual Arousal in Women With Sexual Arousal Disorder
Intranasal bremelanotide significantly improved subjective sexual arousal and desire in premenopausal women with sexual arousal disorder in a placebo-controlled RCT — landmark evidence for melanocortin-based female sexual dysfunction treatment.
Quick Facts
What This Study Found
Intranasal bremelanotide (PT-141) significantly increased subjective sexual arousal, desire, and genital sensation in premenopausal women with sexual arousal disorder in a double-blind, placebo-controlled RCT — landmark evidence leading toward FDA approval for female sexual dysfunction.
Key Numbers
How They Did This
RCT study on pt-141, sexual-health.
Why This Research Matters
Relevant for pt-141, sexual-health.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Intranasal bremelanotide (PT-141) significantly increased subjective sexual arousal, desire, and genital sensation in premenopausal women with sexual
- Evidence Grade:
- strong evidence.
- Study Age:
- Published in 2006.
- Original Title:
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
- Published In:
- The journal of sexual medicine, 3(4), 628-638 (2006)
- Authors:
- Diamond, Lisa E, Earle, Dennis C(2), Heiman, Julia R, Rosen, Raymond C, Perelman, Michael A, Harning, Ronald
- Database ID:
- RPEP-01128
Evidence Hierarchy
Frequently Asked Questions
What was studied?
PT-141 (Bremelanotide) Improves Sexual Arousal in Women With Sexual Arousal Disorder
What was found?
Intranasal bremelanotide significantly improved subjective sexual arousal and desire in premenopausal women with sexual arousal disorder in a placebo-controlled RCT — landmark evidence for melanocortin-based female sexual dysfunction treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01128APA
Diamond, Lisa E; Earle, Dennis C; Heiman, Julia R; Rosen, Raymond C; Perelman, Michael A; Harning, Ronald. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.. The journal of sexual medicine, 3(4), 628-638. https://doi.org/10.1111/j.1743-6109.2006.00268.x
MLA
Diamond, Lisa E, et al. "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.." The journal of sexual medicine, 2006. https://doi.org/10.1111/j.1743-6109.2006.00268.x
RethinkPeptides
RethinkPeptides Research Database. "An effect on the subjective sexual response in premenopausal..." RPEP-01128. Retrieved from https://rethinkpeptides.com/research/diamond-2006-an-effect-on-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.